COVID-19: Our series of regulatory legislation trackers for the Life Sciences & Healthcare industry

COVID-19 presents an unprecedented challenge to the global life sciences industry. Members of our International Life Sciences & Healthcare team, lawyers who have a wealth of hands-on experience and strong relationships with regulatory bodies, have worked together to provide an update in the form of a Q&A for each of the countries we are located. This update aims to provide guidance on the responses of EU and Asia-Pac regulators in the areas of clinical trials, medical devices, market access, public procurement and compulsory licensing.

COVID-19: Legislation Tracker for Medical Devices, read here

COVID-19: Legislation Tracker for Clinical Trials, read here

COVID-19: Legislation Tracker for Public Procurement, read here
 
COVID-19: Legislation Tracker for State Use/Compulsory Licensing, read here

COVID-19: Legislation Tracker for Market Access
, read here
 

 

Latest insights

More Insights
City skyline at dusk

China Cybersecurity: MIIT Releases Data Security Risk Assessment Rules

Jun 24 2024

Read More
card reader and receipt

Open banking rules and GDPR interplay revisited under the EC’s Payment Services Legislation Proposals

Jun 24 2024

Read More
Generative AI

The FCA publishes its expectations of UK financial services firms adopting or deploying the use of AI

Jun 24 2024

Read More